Brent Deibert, MD
Retina Specialist · Boulder, CONPI 1013437029
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (55.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Genentech USA, Inc. accounts for 67.2% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2023 at $5,878 and has fallen 93.2% since, to $400 in 2025.
Across 58 payments — averaging $152.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$6K
- Regeneron Healthcare Solutions, Inc.$590
- Regeneron$389
- Alcon$372
- Genentech, Inc.$263
- Apellis Pharmaceuticals, Inc.$238
- plus $1K from 13 others
What the payments were for
- Consulting fees$4,93556%
- Travel & lodging$6237%
- Food & beverage$3,28137%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 9 | $5,936 |
| Regeneron Healthcare Solutions, Inc. | 9 | $590 |
| Regeneron | 5 | $389 |
| Alcon | 6 | $372 |
| Genentech, Inc. | 3 | $263 |
| Apellis Pharmaceuticals, Inc. | 4 | $238 |
| Dutch Ophthalmic, USA | 3 | $206 |
| Amgen | 2 | $190 |
| Oculus Surgical Inc. | 1 | $123 |
| AbbVie | 3 | $116 |
| Boehringer Ingelheim | 1 | $95 |
| Bausch & Lomb Americas Inc. | 3 | $59 |
| Glaukos Corporation | 1 | $55 |
| Harrow Eye, LLC | 2 | $53 |
| Astellas Pharma US Inc | 2 | $43 |
| Sight Sciences, Inc. | 1 | $42 |
| Alimera Sciences, Inc. | 1 | $33 |
| ANI Pharmaceuticals, Inc. | 1 | $22 |
| Mallinckrodt Enterprises LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,839 in reported general payments places this provider in the 60th percentile of 51 retina specialist providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 112 | $5,647 |
| MoxifloxacinMoxifloxacin Hcl | 68 | $2,143 |
| Atropine Sulfate | 60 | $2,108 |
| ErythromycinErythromycin Base | 62 | $742 |
| Timolol Maleate | 79 | $617 |
| Brimonidine Tartrate | 21 | $402 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 19 | $198 |
| Latanoprost | 35 | $197 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Boulder
- Vlad MateiBoulder$12K
- Murtaza AdamParker$548K
- Alan KimuraDenver$546K
- Brian JoondephDenver$92K
- Talisa ForestAurora$84K
- Sara HaugDurango$59K
- Matthew ManryLongmont$43K
- Ashleigh LevisonLafayette$33K
- Mimi LiuEnglewood$23K
- Moss FenbergDurango$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.